Here’s a frustrating pattern in medical reporting: a study finds something promising, the headlines scream “BREAKTHROUGH,” and suddenly millions of people think a drug is the answer to their prayers. The GLP-1 story is different in one important way, though. The people running this research are actually telling you to pump the brakes.
Cleveland Clinic researchers just presented findings suggesting that GLP-1 medications—the drugs behind Ozempic, Wegovy, and Mounjaro that have become synonymous with weight loss—might slow cancer progression in certain patients. The data looks genuinely intriguing. But before anyone starts demanding their oncologist write a prescription, let’s talk about why the researchers themselves are basically begging us to wait.
The Study That Has Everyone Talking
The Cleveland Clinic analyzed 12,112 patients with early-stage cancers, comparing those who took GLP-1 drugs to a control group using a different diabetes medication called DPP-4 inhibitors. The results were striking on paper: patients on GLP-1s showed significantly lower rates of metastatic progression (that’s cancer spreading to new parts of the body) across six of seven cancer types studied.
For breast cancer, roughly 10% of GLP-1 patients saw progression compared to 20% on DPP-4. In colorectal cancer, it was 13% versus 22%. Lung cancer showed an even starker gap: 10% versus 22%. That’s a massive difference, and it’s why researchers are talking about this at next week’s American Society of Clinical Oncology meeting.
The mechanism? Researchers found that some cancer cells have high levels of GLP-1 receptors, and patients with those receptor-heavy tumors had a 33% lower risk of death. The theory is that GLP-1 drugs might attack cancer cells directly, or at least create an environment where tumors struggle to grow. The drugs could be working through multiple pathways: affecting blood sugar and insulin levels, reducing inflammation, or boosting immune function.
Why This Matters But Also Why It Doesn’t (Yet)
Let’s be clear about what makes this exciting. We’re living in an era where cancer remains one of the leading causes of death globally. Any signal that a widely available medication could help? That’s worth investigating seriously.
But there’s a massive asterisk here, and Dr. Mark Orland, who led the Cleveland Clinic research, is putting it front and center himself. This was an observational study, not a randomized controlled trial. That means researchers weren’t randomly assigning people to take GLP-1s or not; they were looking at real-world data where people had already chosen (or been prescribed) these medications. That introduces all kinds of confounding variables that make it impossible to say the drugs directly caused the cancer benefit.
“We don’t have enough research,” Orland told HuffPost. “It’s too early to act on it.”
The other major problem? The comparison group. The researchers chose DPP-4 inhibitors as their control because, according to Orland, it was “the least contentious of the group.” Translation: DPP-4 drugs are less likely to mess with cancer biology themselves, so any difference would more clearly show what GLP-1s do. But when other researchers compared GLP-1s to a different class of diabetes drugs called SGLT2 inhibitors, the benefit largely disappeared. That’s a red flag that we might be comparing apples to oranges.
The Conflict of Interest You Should Know About
Dr. Orland holds consulting roles and has received research funding from multiple pharmaceutical companies, including Novartis, Bristol Myers Squibb, and others. That doesn’t necessarily mean the research is compromised, but it’s worth knowing when you’re reading claims about a blockbuster drug.
What Happens Now?
The honest answer is that cancer doctors aren’t changing how they treat patients based on this study. Dr. Marcin Chwistek from Fox Chase Cancer Center put it plainly: “It is definitely too early to prescribe GLP-1s solely as a tool for cancer treatment or to prevent metastasis.”
What this research does do is justify the next step: prospective randomized trials where researchers actually assign people to take GLP-1s or a placebo, then follow them to see if the drugs genuinely affect cancer outcomes. Those studies take years.
In the meantime, if you’re a cancer patient who happens to be taking a GLP-1 drug for diabetes or weight management? The research suggests you’re probably not making things worse, and you might be helping. But that’s speculation. And if you’re a cancer patient without diabetes thinking about starting a GLP-1 to prevent tumors from spreading? Don’t. “GLP-1 drugs are not currently approved for cancer prevention,” and taking them off-label for that purpose is exactly how we end up with expensive solutions to hypothetical problems.
The real story here isn’t that we’ve found a cancer cure hiding in the diabetes aisle. It’s that sometimes good science looks like recognizing the limits of your own findings.
